A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aids

American Journal of Ophthalmology

Volumn 133, Issue 4, 2002, Pages 467-474

  Hutcherson, Stephen L ^a   Lanz, René ^b  

^a Cyclix Ltd LLC   (United States)

^b Novartis Ophthalmics AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FOMIVIRSEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINITIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS; MALE; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; THIONUCLEOTIDES; TREATMENT OUTCOME; VITREOUS BODY;

EID: 0036202668     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)01327-2     Document Type: Article

References (33)

1. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region
2. Proof of mechanism of antisense drugs
3. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
4. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs
5. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
6. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides
7. The development of antisense oligonucleotides as antivirals
8. Fomivirsen-a phosphorothioate oligonucleotide for the treatment of CMV retinitis
9. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group
10. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
11. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS; the HPMPC peripheral cytomegalovirus retinitis trial. A randomized controlled trial
12. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized controlled trial
13. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial
14. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group
15. Randomization methods in controlled trials
16. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS
17. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS
18. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting
19. Cytomegalovirus diseases
20. Statistical methodology; IX. Survival analysis
21. Assessment of cytomegalovirus retinitis. Clinical evaluation versus centralized grading of fundus photographs
22. CMV retinitis in the era of HAART
23. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy
24. Changing trends in cytomegalovirus retinitis with highly active anti-retroviral therapy (HAART)
25. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
26. Cytomegalovirus retinitis and viral resistance; 3. Culture results. CMV Retinitis and Viral Resistance Study Group
27. Cytomegalovirus retinitis and viral resistance; ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group
28. Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir
29. New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy
30. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys
31. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy; recommendations of the International AIDS Society-USA panel
32. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group